http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2688313-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae739b067fda3a4d47f77aa1dc7f66c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-25 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2214 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-164 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2008-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56b8cb22919161488d019f960d3d5ed8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96cef2b2f369b3c166e5932195bec6b0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_207153e6f4ffd344a1cd94d5b7fafa90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04024ccb47b693095bc79094e669422a |
| publicationDate | 2009-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2688313-A1 |
| titleOfInvention | Composition for mucosal administration containing agent for enhancing mucosal absorption of peptide drug, and administration method thereof |
| abstract | It is intended to provide an agent for accelerating mucosal absorption enabling oral, transnasal or transpulmonary administration of a peptide drug which shows very poor mucosal absorption and therefore is administered only through injection, and to improve mucosal absorption of a peptide drug through the intestine, lung and nose by allowing the peptide drug to act together with a substance having a C-terminal fragment (C-CPE)of enterotoxin (CPE) produced by Clostridium perfringens which is a bacterium of the genus Clostridium, more specifically, an amino acid sequence formula of C-CPE or a mutant with substitution and/or deletion of one or several amino acid residues of C-CPE. A composition for mucosal administration of the invention has been observed to have a significant effect of accelerating absorption of a peptide drug such as human parathyroid hormone hPTH(1-34), human motilin or human ghrelin in the mucosa of the intestine, lung, nose or the like, and does not have tissue toxicity unlike conventional substances for accelerating mucosal absorption and is excellent in safety. |
| priorityDate | 2007-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1380.